This study found that in patients with cT4b ESCC, the induction regimen of preoperative PD-1 inhibitor combined with albumin-bound paclitaxel + cisplatin resulted in a better pCR rate than did the chemotherapy regimen of albumin-bound paclitaxel + cisplatin alone (23.1% vs. 6.7%). This evidence concerns the gene ALB and esophageal squamous cell carcinoma.